Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
NASDAQ flying pre market up 6.40 in price
Hi they have reversed their decision for now pending news. It's what we are all here for.
Profuction ramped up, new kits, better manufacturing.
https://twitter.com/JLPElecFire/status/1253363719121309697?s=19
Nasdaq up. Volume up, price up, all good and with FDA imminent this will be another NYCT for me. Bought NYCT very early and sold last week. Do not miss this boat guys.
As soon as the next news comes this will fly. Recovering from Covid19 is the next stage and we have the drug.
HospiMedicaDownload Mobile App
Tiziana Life Sciences Accelerate Development of Potential Covid-19 Drug
By HospiMedica International staff writers
Posted on 14 Mar 2020
Tiziana Life Sciences (London, UK), a biotechnology company focused on innovative therapeutics for inflammatory and autoimmune diseases, is expediting development of TZLS-501, a novel, fully human anti-interleukin-6 receptor (anti-IL6R) monoclonal antibody (mAb) for treatment of patients infected with coronavirus COVID-19 (SARS-CoV-2). Tiziana plans to administer TZLS-501 using a proprietary formulation technology. The company has entered into a world-wide license for composition-of-matter of TZLS-501, a fully human mAb targeting IL-6R, with Novimmune, SA, a Swiss biotechnology company in 2017.
Certain patients infected with coronavirus COVID-19 may develop an uncontrolled immune response ("cytokine storm"), resulting in severe damage to lung tissue which could lead to respiratory failure. Excessive production of IL-6 is regarded as a key driver of chronic inflammation and is believed to be associated with severe lung damage observed with COVID-19 infections and acute respiratory illness.
Illustration
Early clinical studies conducted by doctors in China suggest that anti-IL6R mAbs may be used in clinical practice for treatment of COVID-19. Consequently, China's National Health Commission has recommended the use of Roche's blockbuster drug, Actemra® for treatment of patients infected with COVID-19, with serious lung damage and elevated IL-6 levels. Actemra was first approved by the FDA in 2010 for rheumatoid arthritis. Besides Actemra®, Sanofi and Regeneron are currently exploring Kevzara®, an FDA-approved anti-IL-6 receptor therapy for rheumatoid arthritis, for treatment of severe COVID-19.
A recent Chinese study also reported that COVID-19 infection caused clusters of severe respiratory illness such as severe acute respiratory distress syndrome (ARDS). The cytokine, IL-6, a major determinant in the priming of pathogenic T cells to produce an inflammatory response, binds to its receptor subunit IL-6Ra on the cell membrane. The receptor IL-6Ra can be shed in soluble form, sIL6Ra, which binds to circulating IL-6 cytokine in the blood. The downstream signaling from this complex mediates pro-inflammatory effects underlying inflammatory diseases such as rheumatoid arthritis (RA) and ARDS. The company believes that the features of TZLS-501 consisting of its dual mechanism of action to inhibit signaling by the membrane-bound and soluble IL-6 receptor and the rapid depletion of circulating IL-6 cytokines, a major cause of lung damage, provides TZLS-501 with distinct advantages for treatment of COVID-19.
"We believe that the features of TZLS-501 consisting of its dual mechanism of action to inhibit signaling by the membrane-bound and soluble IL-6 receptors along with rapid depletion of circulating IL-6 cytokine, a major cause of lung damage, provides TZLS-501 with
U.S. lawmakers reach deal on $8.3 billion emergency coronavirus bill.
Racing to confront a growing public health threat, key lawmakers in the House and Senate reached a deal on Wednesday to provide $8.3 billion in emergency aid to combat the novel coronavirus, and the House voted Wednesday to approve it.
ADVERTISEMENT
The bipartisan package, which includes nearly $7.8 billion for agencies dealing with the virus and came together after days of rapid negotiations, is substantially larger than what the White House initially proposed in late February.
It also authorizes roughly $500 million to allow Medicare providers to administer tele-health services so that more elderly patients, who are at greater risk from the virus, can receive care at home, according to two of the officials. They spoke on condition of anonymity in advance of a formal announcement.
https://www.google.co.uk/amp/s/uk.mobile.reuters.com/article/amp/idUKKBN2051ED
This is the reason for the rise IMOA
Novacyt S.A. ("Novacyt", the "Company" or the “Group”) Update on CE Mark Approved coronavirus test Paris, France and Camberley, UK – 14 February 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, is pleased to announce that, further to its announcement on 7 February 2020, its subsidiary, Primerdesign Limited, is on schedule to launch a CE-Mark approved nCoV test in the week commencing 17 February 2020. The Primerdesign website has commenced taking orders for the CE-marked test ahead of the planned launch next week. - End – Contacts Novacyt SA Graham Mullis, Chief Executive Officer Anthony Dyer, Chief Financial Officer +44 (0)1276 600081 SP Angel Corporate Finance LLP (Nominated Adviser and Broker) Matthew Johnson / Charlie Bouverat (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking) +44 (0)20 3470 0470 FTI Consulting (International) Victoria Foster Mitchell/Mary Whittow +44 (0)20 3727 1000 victoria.fostermitchell@fticonsulting.com / mary.whittow@fticonsulting.com FTI Consulting (France) Arnaud de Cheffontaines / Astrid Villette +33 (0)147 03 69 47 / +33 (0)147 03 69 51 arnaud.decheffontaines@fticonsulting.com / astrid.villette@fticonsulting.com About Novacyt Group The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates. For more information please refer to the website: www.novacyt.com About 2019-nCoV Researchers at the Chinese Centre for Disease Control and Prevention and their collaborators have sequenced the 2019 novel coronavirus (2019-nCoV) pathogen from patient samples and have found it to be genetically distinct from the severe acute respiratory syndrome (SARS) virus that caused an epidemic in 2002 and 2003, as well as from the Middle East respiratory syndrome (MERS) virus that was detected in 2012.
Will be trying to cover at 2.50 onwards tomorrow
Couple of chunky buys on NEX now. Should be a good afternoon
LOGL expects to receive cash proceeds from this crude oil lifting of c. US$7.0 million. The next lifting, of a similar quantity, is expected to occur within the next four to six weeks.
That's US$14 MILLION IN EIGHT WEEKS. should be 6p minimum. Expect a rally shortly.
The marine vessel, conducting the site survey, arrived at site location yesterday and has commenced its operation which is expected to be completed before the expiration of the approval received from DPR which occurs on 24 March 2020.
Mark Simmonds, who joined Lekoil last month and previously was a minister in the U.K. Foreign Office when David Cameron was prime minister, will lead the investigation alongside Tony Hawkins, who is chief executive of another U.K.-listed oil firm, Columbus Energy.
Once this is sorted LEK will be in a lot better position. Just needed to get past the panic earlier in the week.
Buy,sell drop, buy,sell drop,buy,sell. Finish quids in ;-)